Page 9«..891011..2030..»

You are currently browsing the Nano Medicine category

Design and Synthesis of Gold-Gadolinium-Core-Shell Nanoparticles as Co | IJN – Dove Medical Press

§ November 29th, 2019 § Filed under Nano Medicine Comments Off on Design and Synthesis of Gold-Gadolinium-Core-Shell Nanoparticles as Co | IJN – Dove Medical Press

Fatima Aouidat,1 Sarah Boumati,2 Memona Khan,1 Frederik Tielens,3 Bich-Thuy Doan,2 Jolanda Spadavecchia1

1CNRS, UMR 7244, CSPBAT, Laboratory of Chemistry, Structures and Properties of Biomaterials And Therapeutic Agents University Paris 13, Sorbonne Paris Cit, Bobigny, France; 2UTCBS Chimie ParisTech University Paris Descartes - CNRS UMR 8258 INSERM U1022 Equipe Synthesis, Electrochemistry, Imaging and Analytical Systems for Diagnostics SEISAD, Paris, France; 3General Chemistry (ALGC), Vrije University of Brussel (Free University Brussels-VUB), Brussel, Belgium

Correspondence: Jolanda Spadavecchia Email jolanda.spadavecchia@univ-paris13.fr

Introduction: The development of biopolymers for the synthesis of Gd(III) nanoparticles, as therapeutics, could play a key role in nanomedicine. Biocompatible polymers are not only used for complex monovalent biomolecules, but also for the realization of multivalent active targeting materials as diagnostic and/or therapeutic hybrid nanoparticles. In this article, it was reported for the first time, a novel synthesis of Gd(III)biopolymerAu(III) complex, acting as a key ingredient of core-shell gold nanoparticles (Gd(@AuNPs).Material and methods: The physical and chemical evaluation was carried out by spectroscopic analytical techniques (Raman spectroscopy, UV-visible and TEM). The theoretical characterization by DFT (density functional theory) analysis was carried out under specific conditions to investigate the interaction between the Au and the Gd precursors, during the first nucleation step. Magnetic features with relaxivity measurements at 7T were also performed as well as cytotoxicity studies on hepatocyte cell lines for biocompatibility studies. The in vivo detailed dynamic biodistribution studies in mice to characterize the potential applications for biology as MRI contrast agents were then achieved.Results: Physicalchemical evaluation confirms the successful design and reaction supposed. Viabilities of TIB-75 (hepatocytes) cells were evaluated using Alamar blue cytotoxic tests with increasing concentrations of nanoparticles. In vivo biodistribution studies were then accomplished to assess the kinetic behavior of the nanoparticles in mice and characterize their stealthiness property after intravenous injection.Conclusion: We demonstrated that Gd@AuNPs have some advantages to display hepatocytes in the liver. Particularly, these nanoconjugates give a good cellular uptake of several quantities of Gd@NPs into cells, while preserving a T1 contrast inside cells that provide a robust in vivo detection using T1-weighted MR images. These results will strengthen the role of gadolinium as complex to gold in order to tune Gd(@AuNPs) as an innovative diagnostic agent in the field of nanomedicine.

Keywords: Gd-gold complex, theoretical study, MRI, relaxivity, biodistribution

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Excerpt from:
Design and Synthesis of Gold-Gadolinium-Core-Shell Nanoparticles as Co | IJN - Dove Medical Press

Read the Rest...

Newly Published Research Shows that Hologics Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods – STL.News

§ November 28th, 2019 § Filed under Nano Medicine Comments Off on Newly Published Research Shows that Hologics Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods – STL.News

(STL.News) Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection of vaginitis has been published online in the Journal of Clinical Microbiology. The prospective, multi-center clinical study is the first in the United States to formally validate the performance of the Aptima BV and Aptima CV/TV assays, available from Hologic, Inc. (Nasdaq: HOLX) on its fully automated Panther system.

Vaginitis, a condition that affects millions of women every year, is responsible for up to half of all gynecologic visits in the United States, as well as significant expense to the healthcare system.

As leaders in womens health, we delivered on the need for new, molecular assays for vaginitis that have higher sensitivity and specificity than traditional methods, said Kevin Thornal, Hologics division president, Diagnostic Solutions. This study demonstrates that our assays are better at diagnosing infection than previously available options, which ultimately will ensure women receive the right treatment sooner.

The study notes that women suffering from vaginitis are often underserved by the current paradigm of inaccurate or incomplete diagnosis guiding inadequate or inappropriate treatment. Prior to the introduction of molecular assays, clinicians had no choice but to analyze fresh vaginal discharge samples using a combination of older, subjective methods pH, a potassium hydroxide (KOH) whiff test and Gram-stained microscopic examination to identify the underlying cause.

The new Aptima molecular tests circumvent barriers to accurate diagnosis associated with the use of these traditional methods, including absence of proper equipment, lack of training, and access to microscopy in the clinic. These and other barriers can result in many women being misdiagnosed, which the study says can lead to incorrect, misguided or prolonged treatment. In fact, separate research shows that when treatment is based on diagnosis with these traditional methods, more than half of women with vaginitis experience recurring symptoms.

Many women try to self-diagnose and self-treat before eventually visiting a healthcare provider, assuming that abnormal vaginal discharge, itching or irritation is due to a simple yeast infection, said the studys corresponding author, Dr. Jane R. Schwebke, professor of medicine at the University of Alabama at Birmingham. But BV or TV left untreated or improperly treated can put women at risk for a variety of complications, including an increased chance of getting sexually transmitted infections (STIs) such as chlamydia or HIV, pelvic inflammatory disease, and pregnancy-related risks including premature delivery, low birth weight and infertility. These objective and comprehensive diagnostic tests will mitigate such risks and allow clinicians to feel more confident that theyre properly treating women.

BV (bacterial vaginosis) is the most common vaginal infection in the U.S., affecting an estimated 21 million women a year. Together with CV (vulvovaginal candidiasis) commonly known as yeast infections and TV (trichomonas vaginalis), individually or in combination, these three vaginal infections cause about 90 percent of vaginitis infections. Each cause of vaginitis has its own characteristics, consequences and treatment recommendations, which vary between BV, CV and TV, further reinforcing the need for accurate diagnoses.

Study Details

Subjects in the multi-center, cross-sectional diagnostic accuracy study for the Aptima BV and Aptima CV/TV assays were at least 14 years old with symptoms of vaginitis such as abnormal vaginal discharge, vaginal odor, genital itching or irritation, pain or discomfort during sexual intercourse or urination, edema or erythema. They were enrolled at 21 U.S. sites, including clinical research centers and emergency medicine, family planning, public health, STI and family medicine/obstetric-gynecologic (OB-GYN) facilities between June and October 2018.

Patient- and clinician-collected vaginal swab samples obtained from women with symptoms of vaginitis were tested with the Aptima BV and Aptima CV/TV assays. The prevalence of infection was similar for clinician- and patient-collected samples: 49 percent for BV, 29 percent for CV due to the Candida species group, 4 percent for CV due to C.glabrata, and 10 percent for TV. Sensitivity and specificity estimates for the tests in clinician-collected samples were, respectively, 95.0 percent and 89.6 percent for BV, 91.7 percent and 85.8 percent for the Candida species group, 84. percent and 99.1 percent for C. glabrata, and 96.5 percent and 98.9 percent for TV. Sensitivity and specificity were similar in patient-collected samples.

Hologic offers 16 FDA-cleared assays on the Panther system that detect more than 20 pathogens, offering the only high-throughput molecular diagnostic platform in the U.S. to combine comprehensive sexual health, cervical health, viral load, respiratory testing and open channel functionality on a fully automated system.

CLICK to VIEW SOURCE

291

Go here to see the original:
Newly Published Research Shows that Hologics Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods - STL.News

Read the Rest...

The Shocking history of the Torpedo Ray and other Electric Fish – Port St. Joe Star

§ November 28th, 2019 § Filed under Nano Medicine Comments Off on The Shocking history of the Torpedo Ray and other Electric Fish – Port St. Joe Star

Many of us are aware of the lesser electric ray, Narcine brasiliensis, some perhaps too familiar considering the nearly 35-volt jolt it can deliver if touched. Less common locally is the related Atlantic torpedo, Torpedo nobiliana.

We intuitively understand the physical basis of an electric shock, with our lives dependent on an electrical infrastructure. Nevertheless, it is fascinating to reflect back in history, imagine how an electrical shock from a fish was viewed when all of nature was interpreted on the basis of four elements, air, earth, fire, and water. In contrast, electricity is a phenomenon of relatively recent history, popularized beginning in the 18th century by Benjamin Franklin flying his kite in a thunderstorm.

First, it is instructive to review the diversity of electric fish. Mostly, we think of electrogenic fish that produce an electric organ discharge (EOD). Then there are fish that are electrosensory, a sense we do not possess. Many fish are both electrosensory and generate EODs.

Fish can be strongly or weakly electrogenic. The former includes skates and rays, (the genus Torpedo contains 10 species, some generating EODs up to 220 volts), stargazers (to 50 volts), and the electric Nile catfish Malapterus electricus (to 350 volts). Most familiar is the South American electric eel, Electrophorus electricus, with EODs of up to 700 volts, jolts known to stun and disable a horse.

In contrast, weakly electric fish generate EODs around 1 volt, several hundred species in all including many common in the aquarium trade such as elephantnose and knifefishes. These fish are also electrosensory and communicate with each other electrically. Moreover, by monitoring objects that distort their own electric fields they can electrolocate, analogous to sonic location used by bats and porpoises, active mechanisms especially useful in the dark.

Other electrosensory fish are passive (no EODs), detecting the electrical fields of both animate and inanimate objects as weak as 1 nanovolt (10-9 V) per centimeter. To illustrate this extraordinary sensitivity consider that a shark can detect a flounder buried in the sand, and can navigate, monitoring its own electric field as it swims, its body acting as a conductor moving through the earths magnetic field, the biological equivalent of an electricity generator. The passive electrosense is a primitive feature found in lampreys, all elasmobranchs (sharks, skates and rays), sturgeon and paddlefish. Essentially an aquatic sensory mechanism, the duckbill platypus, a mammal, has developed a parallel electrosense used to detect prey.

The shocking history origins deal primarily with torpedoes abundant in Mediterranean waters and brought to the attention of scholars, physicians and philosophers during the classical Greco-Roman era. The earliest reference to torpedoes was in Hippocratic writings in the 5th century B.C. Plato and Socrates (4th century B.C.) alluded to their powers as magic, benumbing the mind, whereby the flat sea torpedo torpifies those who come into contact. The Greeks referred to the effect as nrk, from which narcotic, narcosis, narcotize were derived based on the fishs ability to cause numbness, torpor, and involuntary muscle twitches.

Aristotle (374-322 B.C.), writing in his Historia Animalium, noted its specialized numbing as a purposeful intelligence that it used to capture prey. He was supplied specimens by local fishermen and by Alexander the Great. These fishermen reported that the mysterious force of the torpedo could be felt even at a distance when touched holding a metal rod (trident) or the salty lines of a fishing net.

Pliny the Elder (1st century A.D.), the great Roman naturalist, wrote in his 37 volume Naturalis Historia that if only touched with the end of a spear or staff, this fish has the property of benumbing even the most vigorous arm and of riveting the feet of the runner. He interpreted the shock as an odor of emanation from the fish, a poison that could run up a spear and kill a man, even a horse, a mixture of science and fable.

Greco-Roman medical literature included many therapeutic uses for the torpedo discharge, of course without any idea of the force electricity. Among some 271 remedies ascribed to Scribonius (3 B.C.-54 A.D.) were treatments using torpedoes for headaches to gout. The latter, foot pain or podagra, was common among Roman aristocrats given their rich diets and lead poisoning from wine containers. The foot placed on a live torpedo on the moist shore relieved gout pain up to the knee. Headache relief involved placing a live torpedo on the spot of the pain but required subsequent removal lest ability to feel be taken away. This numbing effect is not so far-fetched knowing now that electrical stimulation is used clinically to relieve pain and thought to release endorphins.

In addition to relief of headache pain, Discorides (1st century A.D.) used torpedoes to treat a condition of the seat, now interpreted to mean application to the prolapsed seat (prolapsus ani in Latin), that is, hemorrhoids. This form of electrotherapy is potentially valid given that electrical stimulation can cause constriction of blood vessels and hemorrhoidal shrinkage.

Galen (129-200 A.D.), the most accomplished physician and philosopher in Roman antiquity, also tested the shock of the torpedo, finding it useful in treating headaches. In describing its analgesic remedy, he likened the effect to a cold venom, some form of corpuscular matter. He equated hand numbness transmitted through the trident to the lodestone (a magnet) effect in which a body can acquire the power of a separate object.

The immobilizing actions of the torpedo also captured the imagination of ancient poets who suggested that catching a torpedo can make an angler remorseful. Oppian (2nd century A.D.), writes poetically that the Cramp-fish (torpedo) paint their magick wands, where icy torch the strongest fin commands one touch of hers dams up the vital Flood, Contracts the Nerves, and clots the stagnate Blood. Torpedoes also appeared prominently in Mediterranean paintings and pottery.

Authors from classical antiquity significantly influenced how torpedoes, along with the Nile catfish, were perceived well into the Middle Ages, a period during which Christianity and Islam emerged along with a decline in the spirit of scientific investigation, the Dark Ages. Physicians still used torpedoes for head pain and podagra as specified in medical texts. Byzantine writings concerning nrk were essentially compilations from the previous classical era and associated the magical powers with various occult practices.

Well into the Renaissance, despite advances in architecture, medicine, and science, there was no further insight into the nature of the discharge. By the 16th century, European exploration and conquest had generated considerable interest in the torporific (electric) eel that horrified natives along the Orinoco River in South America. Still, the only explanation available was that the torpedo discharge was mechanical, associated with violent contractions in the fish.

The discharge itself was interpreted at the time according to atomistic theories of sensation attributed largely to Galileo, whereby microscopic pores, canals and glands produced minute corpuscles (atoms) used to explain multiple physiological processes including perspiration. This was incorporated in Stefano Lorenzinis (1678) corpuscular theory attributing numbness to corpuscles (molti corpuscoli) that entered the hand to block nerves as a result of touching the fish. The mechanical theory was later discredited since contractions by the torpedo proved to be invisible, unrepeatable, and any movements were no doubt affected by the tremor induced in the experimenters hand in response to the shock.

Electricity as a physical entity became established in mid-17th century Europe, confirmed scientifically by the 18th using instruments such as the Leyden jar, a capacitor that was introduced into the publics imagination by Abbe Jean-Antoine Nollet (1700-1770), in a demonstration before royal onlookers in Versailles that 180 hand-holding grenadiers who completed the circuit leaped in unison at its discharge.

These instruments were capable of producing sparks, akin to static electricity we can generate by stroking fur or amber, and were seemingly related to the demonstration of atmospheric electricity by Benjamin Franklin. Self-educated, Franklin abandoned his lucrative printing business in 1748 to study electricity and later moved to England in 1757 to join the Royal Society of London, where he contributed prominently to developments in fish electricity. He also is credited with the concept of polarity, based on his theory that lightning is charged differently between clouds (negative) and land (positive), and concluding that natural and man-made electricity are the same.

As interest in electricity grew in the 18th century, it led to numerous attempts, including by Franklin, to use electrotherapy to treat palsies, hysteria, and other paralyzing illnesses. Still, despite the ancient history of torpedo therapeutics, no scientific understanding of animal electricity was yet available. Although nerves were envisioned as conduits to the brain as early as the 4th century B.C., conveyance (conduction) along the nerve was still attributed variously to ethereal spirits, fluids, or mechanical vibrations.

As interest in animal electricity continued to grow, electric fish contributed significantly to the eventual electrical basis of physiological function in both nerve and muscle. A major contribution from the Dutch, with settlements in Guiana, S.A., came from awareness of the more powerful electric eel whose discharge was equated with that of the Leyden jar, both capable of knocking a person to the ground. The only difference was that neither spark (eq., lightning) nor weak crackling sound (eq., thunder) could be elicited from the eel, facts that contributed to remaining resistance to the idea of fish electricity.

An American physician who worked briefly in Guiana (Edward Bancroft, 1744-1821) presented evidence that shocks from the torporific eel traveled up the fishing line and could be felt by several people holding hands (in series). John Walsh (1726-1795), a wealthy English colonel with an interest in natural history provided singular evidence for the electrical nature of Torpedo.

Armed with a series of experiments outlined by his collaborator, Benjamin Franklin, Walsh traveled to La Rochelle and nearby lIsle de R on the French Atlantic coast where the rays were abundant. Using public demonstrations he showed that the discharge could be felt 40 feet away when connected to the fish by a wire, that up to eight persons holding hands in series were affected, and that two persons, one touching the upper surface of the fish, the other the lower surface, only felt the shock when they completed the circuit by holding hands. In letters back to Franklin, Walsh concluded that the effect is certainly torpedinal electricity.

His work was forwarded to Henry Cavendish (1731-1810), the brilliant chemist (discoverer of oxygen), physicist and member of the Royal Society (along with Walsh, Franklin, Bancroft and other notables), who provided quantitative explanations supporting fish electricity. Franklin returned to the United States in 1775 in fear of arrest as a spy as progression toward the American Revolution became obvious. Ironically, it was August 1, 1776, when Walsh finally succeeded in demonstrating the convincing spark from a fish discharge, made possible by the arrival of a live electric eel from Guiana whose discharge was 10 times greater than the torpedo.

The torpedo and electric eel were important in the realization that animals function electrically. As such they had great influence on two Italian physician scientists, Luigi Galvani (1773-1798) and Alessandro Volta (1745-1827). Galvanis experiments led him to propose that electricity was inherent in the tissues of the nerve by demonstrating that frog leg muscles twitched when the [motor] nerve was stimulated with a weak electrical current. One such experiment used long wires connected to an electrical device in the room. This is known to have inspired Mary Shelley to create Frankenstein in her 1817 saga by attracting the electrical activity from a lightning storm.

Volta claimed that the electricity was not intrinsic to the nerve but rather originated in the metals Galvani used to touch the nerve. His own experiments with the frog used a pile or battery that he is credited with inventing. This first battery, dissimilar metals sandwiched around moistened cardboard, was inspired in turn by the electric organ of the torpedo. From these signature experiments, preceded by work through the ages, it is clear that torporific fishes have played a major role in shaping civilization through the life sciences and medicine.

Lon Wilkens, an emeritus professor of neuroscience at the University of Missouri-St. Louis, lives on St. George Island.

Read more:
The Shocking history of the Torpedo Ray and other Electric Fish - Port St. Joe Star

Read the Rest...

TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599 – BioSpace

§ November 27th, 2019 § Filed under Nano Medicine Comments Off on TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599 – BioSpace

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 27, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced today that the first patient has been enrolled in EXCELLENCE, the Phase III pivotal clinical trial for TLC599 in patients with osteoarthritis (OA) knee pain. TLC599 is a non-opioid, proprietary BioSeizer sustained release formulation of dexamethasone sodium phosphate (DSP) intended to manage OA pain for up to six months.

The initiation of EXCELLENCE was supported by findings from a Phase II, randomized, double-blinded, placebo-controlled clinical trial in patients with OA of the knee, in which TLC599 12mg demonstrated statistically significant and clinically meaningful improvement in pain relief in both the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS) scores compared to placebo from Day 3 all the way through the end of the study at 24 weeks. Over half of the patients in the TLC599 group had a durable response, maintaining at least 30% pain reduction in both WOMAC and VAS pain scores at all visits through the entire 24 weeks.

EXCELLENCE, the Phase III, multi-center, randomized, double-blind, placebo- and active comparator-controlled pivotal study, will evaluate the efficacy and safety of a single as well as a repeat dose of TLC599 12mg in approximately 500 patients with moderate to severe symptomatic knee OA with radiographic severity of Kellgren-Lawrence (KL) Grade 2 to 3. The trial will take place across 40-50 sites in the US and Australia. On Day 1, patients are randomized in a 2:1:1 ratio to receive an intraarticular injection of TLC599, DSP (a glucocorticoid widely used in the treatment of joint pain) or placebo (normal saline). At Week 24, patients can receive a second blinded injection of TLC599 or placebo. Patient enrollment is expected take about one year; all patients will be followed for a total of 52 weeks.

The primary efficacy endpoint is the magnitude of pain relief by WOMAC Pain score versus placebo at Week 16 and Week 40. Key secondary endpoints include the magnitude of pain relief by WOMAC Pain or Function scores versus placebo or DSP at Weeks 16, 20, 24 and through 52 weeks as well as patient global impression of change (PGIC).

We are optimistic about the results of EXCELLENCE, remarked George Yeh, President of TLC. If results are positive, the data would support a New Drug Application (NDA) for TLC599 with the US Food and Drug Administration (FDA). And if approved for repeat administration by the FDA, two simple injections of TLC599 would potentially alleviate the pain associated with OA for a full year, deterring the use of addictive opioids and avoiding the need for knee replacement surgery.

More information on EXCELLENCE can be found on ClinicalTrials.gov.

About TLC599

TLC599 is a BioSeizer sustained release formulation of DSP intended for the treatment of OA pain. Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. An in vivo toxicity study by staining of the cartilage showed TLC599 to be cartilage sparing compared to current treatments. In a Phase II clinical trial, a single injection of TLC599 resulted in statistically significant and clinically meaningful improvement in pain relief in both WOMAC and VAS scores compared to placebo through 24 weeks. EXCELLENCE, a multi-center, randomized, double-blind, placebo- and active comparator-controlled pivotal Phase III clinical trial to evaluate the efficacy and safety of both single and repeated doses of TLC599, is currently underway.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD). TLC believes that its deep experience with liposome science allows a combination of onset speed and benefit duration, improving active drug concentrations while decreasing unwanted systemic exposures. TLCs BioSeizer technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX active drug loading technology has been proven in two approved drugs and is designed to alter the systemic exposure of a drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients, and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, without limitation, statements regarding TLCs expectations regarding the clinical development of TLC599, the clinical benefits of TLC599 for knee osteoarthritis, the timing, scope, progress and outcome of the clinical trials, and the anticipated timelines for the release of clinical data. Words such as may, believe, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and TLC599 or any of our other product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval. Other risks are described in the Risk Factors section of TLCs annual report on Form 20-F for the year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLCs expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

Go here to see the original:
TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599 - BioSpace

Read the Rest...

Here’s what you need to know about superbugs in the ‘post-antibiotic era’ – The Province

§ November 27th, 2019 § Filed under Nano Medicine Comments Off on Here’s what you need to know about superbugs in the ‘post-antibiotic era’ – The Province

By Danielle Edwards

Antibiotics are considered one of the greatest breakthroughs in modern medicine. But in the United States, 35,000 people die a year after succumbing to germs that have evolved the ability to fend off the drugs designed to kill them. Its why two reports from the Centres for Disease Control (CDC) and an expert panel commissioned by the Council of Canadian Academies (CCA) have rung the alarm on antibiotic resistance, saying that millions of lives worldwide are at risk. Heres what you need to know about the rise of superbugs and why some experts are calling it the worlds deadliest health crisis.

How are antibiotics made?

Antibiotics are actually created naturally by bacteria to kill off neighbouring predatory organisms in an ecosystem.

In fact, Alexander Fleming made his world-changing discovery of penicillin in 1928 after observing a type of mould had antibiotic properties.

Scientists would go on to harvest soil samples to isolate more germ-killing medicine from microbes that organically evolved defence mechanisms.

Brett Finlay, a microbiology professor at the University of British Columbia, said its a simple process of natural selection.

When you put a selection pressure on any microbe, a small number of them are going to figure out how to avoid it if they can, he said.

Finlay, who sat as the chair for the CCA panel, added that microbes could evolve to reinforce their outer shells. The problem, he said, starts when those resistant microbes start to multiply.

Whats causes antibiotic resistance?

Mass antibiotic use started in earnest during the Second World War, and with large-scale usage came faster resistance rates. Finlay explained that, unlike humans, bacteria can much more effectively swap genetic information.

Once you have a resistance gene, which then resists these antibiotics in the population, it then spreads from microbe to microbe quite easily, he said.

The drugs are now used in several sectors. Though the CCA report stressed there was no one area to blame, it did list factors that have contributed to the weakening of antibiotic treatments.

The CDC estimates doctors prescribe 47 million courses of antibiotics yearly for infections that dont need them in the U.S.

The bulk of antibiotics in Canada 78 per cent are used in the production of livestock, some of them the same drugs used to treat human pathogens, which ups the chances of those germs developing resistance, as well.

Whats the worst-case scenario?

Both the reports warn of the wide-reaching effects of antibiotic resistance, like lower food production, increased hospital costs and the onset of millions of infections with no way to treat them.

Stop referring to a coming post-antibiotic era its already here, CDC Director Robert Redfield said in a letter accompanying the organizations report. You and I are living in a time when some miracle drugs no longer perform miracles and families are being ripped apart by a microscopic enemy.

Bacteria that cause illnesses like urinary tract infections and gonorrhea are some of the microbes researchers are most concerned about, especially since its becoming nearly impossible to develop new antibiotics, Finlay said.

Financial and scientific obstacles meant that no new major classes of antibiotics were approved to treat infections between 1962 and 2000.

In 2018, 26 per cent of diagnosed infections in Canada required further treatment and that number could jump to 40 per cent by 2050.

While the CDC said the number of infection-related deaths has decreased since it released a 2013 report on the resistance phenomenon, more than 2.8 million antibiotic-resistant infections are diagnosed in the U.S. every year.

There could be an enormous economic cost, as well. The CCA report projected the phenomenon could reduce Canadas GDP by up to $21 billion per year and rack up $8 billion in healthcare costs over the next thirty years.

Mitigation efforts?

Fighting antibiotics with antibiotics isnt the answer, the reports note. But they both say infection prevention, which includes good old handwashing, is one of the best ways to cut down on antibiotic use. Fewer infections means less need to prescribe the germ-killing drugs.

And medical innovations, like phage therapy which uses viruses to kill bacteria, could mean the end of our dependence on antibiotics.

Finlay said one of the biggest ways to slow the increase in resistance is stewardship making sure antibiotics are only used when theyre absolutely necessary.

You dont need antibiotic-containing detergents (that) youre using on your countertops to clean them. You dont have to use hand sanitizer every time you go out the door, he said.

Its not all bad news. There have been government efforts to lower antibiotic use (Health Canada announced last year the drugs could only be used for livestock with a valid prescription), but Finlay said it will take combined efforts from the healthcare sector and governments to take on the threat.

Its going to affect everyone, no one is immune from this, said Finlay. Whatever station in life you are, you get infections, and you need antibiotics. And if theyre not there, you suffer.

Read more:
Here's what you need to know about superbugs in the 'post-antibiotic era' - The Province

Read the Rest...

Sore muscles after activity: What it means and relief – Medical News Today

§ November 27th, 2019 § Filed under Nano Medicine Comments Off on Sore muscles after activity: What it means and relief – Medical News Today

Any physical activity that places too much or unusual strain on the muscles can lead to soreness. Everyone can experience muscle soreness, even people who exercise regularly and have good physical fitness.

Muscle soreness can be uncomfortable and disruptive. However, the pain typically disappears within a few days.

This article outlines the causes of muscle soreness and the typical duration of symptoms. We also list the treatments that may help to relieve muscle soreness, along with research into their effectiveness.

During physical activity, the body's muscles extend and contract to support movement. Prolonged or repetitive physical activity can overexert the muscles. This activity can lead to muscle soreness.

Overexertion and muscle soreness are more likely to occur after physical activity that differs from normal. This could be due to:

Muscle soreness usually occurs several hours after physical activity. For this reason, doctors refer to the condition as delayed onset muscle soreness (DOMS). Most people experience DOMS at some point, regardless of their physical fitness.

The exact cause of DOMS is still unclear. Some experts believe it may be due to microscopic tears in the muscle fibers, which can develop during exercise. They believe that muscle soreness is the result of the body healing these tears. DOMS is not due to a buildup of lactic acid in the muscles.

According to the American College of Sports Medicine (ACSM), muscle soreness usually begins 1224 hours following exercise. The muscle soreness then tends to peak around 2472 hours after the exercise. After this time, the pain should start to go away.

The level of soreness a person feels during DOMS depends on the type, duration, and frequency of the activity that caused the pain.

It is possible to continue exercising with muscle soreness, but it can be uncomfortable.

Sharp pains that occur immediately after activity could be a sign of injuries, such as strains or sprains. These injuries are the result of a muscle, tendon, or ligament becoming stretched or torn and are more severe than DOMS, possibly requiring medical attention.

Muscle soreness is normal and rarely requires medical attention. In most cases, symptoms go away on their own within a few days. In the meantime, it is best to avoid putting too much strain on the injured muscles.

People sometimes recommend the following treatments to alleviate muscle soreness following exercise:

Massage: A qualified sports massage therapist or physiotherapist can provide massages for alleviating muscle soreness. Massages increase blood flow to the injured area, which may promote healing and help to relieve the pain.

Heat therapy: Taking a warm bath or applying heat pads can also stimulate blood flow to the injured muscles. Heat therapy tends to offer only temporary symptom relief.

Cold therapy: Cold packs or immersion in cold water can reduce inflammation and swelling in the muscles. Cold therapy is, therefore, useful as a longer-term treatment for muscle injuries.

Light exercise: Keeping the muscles active may help to reduce pain. It is important to keep the intensity light and avoid movements that put too much strain on injured muscles. Examples of light exercises include walking and gentle stretching.

Pain medication: Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) can help to reduce muscle inflammation and associated pain.

A 2012 meta-analysis investigated the effectiveness of four popular DOMS treatments. The meta-analysis included 35 studies, each of which investigated one of the following treatments:

The meta-analysis revealed that massage was effective in treating the signs and symptoms of DOMS in some people. However, the effect was small and was not significant across the group as a whole. There was no evidence to support the use of cryotherapy, stretching, or light exercise in treating DOMS.

A 2011 meta-analysis also found that stretching before or after exercise does not lead to a noticeable reduction in DOMS.

A 2016 meta-analysis investigated whether a type of cryotherapy called cold water immersion (CWI) helps to alleviate muscle soreness. The results showed that CWI was slightly more effective than no treatment. Bathing in water temperatures between 11C15C for 1115 minutes provided the best results.

Overall, these studies indicate that there are few scientifically proven treatments for DOMS. Those that are effective appear to provide only a slight benefit. Nonetheless, some people may find the treatments helpful.

Importantly, while a treatment may help to alleviate pain, it will not undo the underlying muscle damage or improve muscle function.

While it is not possible to completely prevent DOMS, a person can take steps to reduce the severity of symptoms.

According to the ACSM, the best way to do this is to build up slowly to any changes in exercise routines. This cautious approach will give the muscles time to adapt to the changes they are experiencing.

Physical activity can sometimes lead to DOMS. The symptoms of DOMS usually appear several hours after physical activity and may last up to 72 hours.

While DOMS can be uncomfortable, it does not require medical attention. People sometimes recommend home remedies to alleviate the symptoms, but there is little scientific evidence to support this. It may be necessary to try multiple treatments before finding one that helps in some way.

People may experience a sharp pain during or immediately after physical activity. This sensation could signal a more serious injury, such as a strain or sprain. People should see a doctor if the pain persists or worsens.

Continued here:
Sore muscles after activity: What it means and relief - Medical News Today

Read the Rest...

Newly Published Research Shows that Hologics Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods – Yahoo Finance

§ November 27th, 2019 § Filed under Nano Medicine Comments Off on Newly Published Research Shows that Hologics Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods – Yahoo Finance

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

More sensitive and specific assays for vaginitis reduce the incorrect, misguided or prolonged treatment that can result from older, subjective testing methods

Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection of vaginitis has been published online in the Journal of Clinical Microbiology. The prospective, multi-center clinical study is the first in the United States to formally validate the performance of the Aptima BV and Aptima CV/TV assays, available from Hologic, Inc. (HOLX) on its fully automated Panther system.

Vaginitis, a condition that affects millions of women every year, is responsible for up to half of all gynecologic visits in the United States, as well as significant expense to the healthcare system.1

As leaders in womens health, we delivered on the need for new, molecular assays for vaginitis that have higher sensitivity and specificity than traditional methods, said Kevin Thornal, Hologics division president, Diagnostic Solutions. This study demonstrates that our assays are better at diagnosing infection than previously available options, which ultimately will ensure women receive the right treatment sooner.

The study notes that women suffering from vaginitis are often underserved by the current paradigm of inaccurate or incomplete diagnosis guiding inadequate or inappropriate treatment. Prior to the introduction of molecular assays, clinicians had no choice but to analyze fresh vaginal discharge samples using a combination of older, subjective methods pH, a potassium hydroxide (KOH) whiff test and Gram-stained microscopic examination to identify the underlying cause.

The new Aptima molecular tests circumvent barriers to accurate diagnosis associated with the use of these traditional methods, including absence of proper equipment, lack of training, and access to microscopy in the clinic. These and other barriers can result in many women being misdiagnosed, which the study says can lead to incorrect, misguided or prolonged treatment.1 In fact, separate research shows that when treatment is based on diagnosis with these traditional methods, more than half of women with vaginitis experience recurring symptoms.2

Many women try to self-diagnose and self-treat before eventually visiting a healthcare provider, assuming that abnormal vaginal discharge, itching or irritation is due to a simple yeast infection, said the studys corresponding author, Dr. Jane R. Schwebke, professor of medicine at the University of Alabama at Birmingham. But BV or TV left untreated or improperly treated can put women at risk for a variety of complications, including an increased chance of getting sexually transmitted infections (STIs) such as chlamydia or HIV, pelvic inflammatory disease, and pregnancy-related risks including premature delivery, low birth weight and infertility.2,4 These objective and comprehensive diagnostic tests will mitigate such risks and allow clinicians to feel more confident that theyre properly treating women.

BV (bacterial vaginosis) is the most common vaginal infection in the U.S., affecting an estimated 21 million women a year.3 Together with CV (vulvovaginal candidiasis) commonly known as yeast infections and TV (trichomonas vaginalis), individually or in combination, these three vaginal infections cause about 90 percent of vaginitis infections.2,4 Each cause of vaginitis has its own characteristics, consequences and treatment recommendations, which vary between BV, CV and TV, further reinforcing the need for accurate diagnoses.

Study Details

Subjects in the multi-center, cross-sectional diagnostic accuracy study for the Aptima BV and Aptima CV/TV assays were at least 14 years old with symptoms of vaginitis such as abnormal vaginal discharge, vaginal odor, genital itching or irritation, pain or discomfort during sexual intercourse or urination, edema or erythema. They were enrolled at 21 U.S. sites, including clinical research centers and emergency medicine, family planning, public health, STI and family medicine/obstetric-gynecologic (OB-GYN) facilities between June and October 2018.

Patient- and clinician-collected vaginal swab samples obtained from women with symptoms of vaginitis were tested with the Aptima BV and Aptima CV/TV assays. The prevalence of infection was similar for clinician- and patient-collected samples: 49 percent for BV, 29 percent for CV due to the Candida species group, 4 percent for CV due to C. glabrata, and 10 percent for TV. Sensitivity and specificity estimates for the tests in clinician-collected samples were, respectively, 95.0 percent and 89.6 percent for BV, 91.7 percent and 85.8 percent for the Candida species group, 84.7 percent and 99.1 percent for C. glabrata, and 96.5 percent and 98.9 percent for TV. Sensitivity and specificity were similar in patient-collected samples.

Story continues

Hologic offers 16 FDA-cleared assays on the Panther system that detect more than 20 pathogens, offering the only high-throughput molecular diagnostic platform in the U.S. to combine comprehensive sexual health, cervical health, viral load, respiratory testing and open channel functionality on a fully automated system.

For more information on the Aptima BV and Aptima CV/TV assays, visit http://www.hologic.com.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving womens health and well-being through early detection and treatment. For more information on Hologic, visit http://www.hologic.com.

Hologic Forward-Looking Statements

This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologics diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, Aptima, Panther and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Source: Hologic, Inc.

____________________

View source version on businesswire.com: https://www.businesswire.com/news/home/20191125005200/en/

Read more:
Newly Published Research Shows that Hologics Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods - Yahoo Finance

Read the Rest...

2 newborns sickened by tick bites could signal an increase in infections among babies – CNN

§ November 27th, 2019 § Filed under Nano Medicine Comments Off on 2 newborns sickened by tick bites could signal an increase in infections among babies – CNN

The infants, one girl and a boy, were taken to hospitals in New York because they were experiencing common signs of infection: rashes, fever and irritability.

What wasn't common to the doctors who treated the babies were the more unusual symptoms: anemia, an elevated heart rate and a low blood platelet count.

The doctors, from Stony Brook Children's Hospital and Hampton Community Healthcare in New York, said that the infants were suffering from tick-borne infections that are rare in newborns because of limited exposure.

"These two cases really underscore just the extent to which these ticks are spreading and bringing the tick-borne infections along with them," said Dr. Andrew Handel, who helped treat the babies and practices in the Pediatric Infectious Diseases division at Stony Brook Children's Hospital. "As we see those ticks being spread throughout the community, we also see a growing population of individuals who can become infected with them."

Changes in land use patterns may contribute to the spread of ticks, as suburban development in forest areas means ticks and animal hosts are in close contact.

Unusual cases

A 6-week-old previously healthy infant boy was brought to a hospital in June after experiencing symptoms including irritability, poor feeding, vomiting and high fever.

Lab results showed the boy was also anemic, with a low blood platelet count.

He was treated with antibiotics and was transferred to Stony Brook Children's Hospital, where more testing revealed worsening anemia and blood platelet counts, as well as elevated levels of liver enzymes, which hint at an injured liver and a risk for liver disease.

His mother remembered seeing a bloody "flea" on her son's arm 20 days before his symptoms began. The family lives in a tick-endemic area, their home surrounded by tall grasses. Tick-borne diseases occur most frequently in the Northeast, mid-Atlantic and Upper Midwest.

Another round of antibiotics was started, but the boy's hemoglobin level severely dropped, requiring a packed red blood cell transfusion.

In August, a 5-week-old previously healthy infant girl was brought to the hospital emergency department because of a fever and an unusual rash.

Her parents reported removing an engorged black bug from her ear six days before her symptoms started. Their baby was rarely outdoors, although the family's dogs walked outside.

"Pets are well-known to carry ticks into the home. So take avoidance maneuvers," said Dr. Paul Auwaerter, clinical director of infectious diseases at John Hopkins University School of Medicine. "Shampoo or collars can be helpful." Auwaerter was not involved in either of the case studies.

The baby girl's heart was beating at a higher than normal rate. She was diagnosed with early disseminated Lyme disease, meaning the bacteria causing the disease had spread throughout her body.

Both babies' illnesses were remedied by rounds of antibiotics, but because no data exists to guide Lyme disease management in newborns, doctors referred to the American Academy of Pediatrics Red Book, which offers care solutions for infectious diseases.

There are also no clinically validated or FDA-approved tests for tick-borne infection for newborns.

Many questions remain, but the doctors thought that reporting their "ideas and conclusions that we came up with while treating these two infants might be helpful for future providers who come across similar cases," Handel said.

For older groups, there is testing to find tick-borne illnesses earlier and treatments that resolve symptoms. Both help to prevent long-term complications.

Protecting your kids and pets from tick bites

Children have a higher risk of getting Lyme and other tick-borne diseases because they tend to be more exposed to them.

"Kids, especially when they get beyond a certain age, bathe themselves, and they're not really looking for ticks," Auwaerter said. "Children tend to be outdoors more in play."

Having pets leaves your family more at risk, too. They can carry ticks in from outside, and sometimes the ticks are hard to find because of a pet's fur. Pet owners can talk with their veterinarians about medications for preventing tick bites.

There are ways you can protect yourself, your kids and your pets getting tick-borne diseases -- most importantly, "doing your nightly tick checks," Handel said.

The CDC recommends also avoiding high grasses, using insect repellent, bathing or showering as soon as you get inside, conducting full body tick checks and putting clothes in the dryer on high heat to kill ticks.

Although tick-borne illnesses are rare for newborns, doctors should consider them if they meet an infant who has a fever, an unusual rash or other signs of infection and lives in a tick-endemic area, Handel said.

"We don't want parents to hear about these cases and have an excess of anxiety that this could happen to their child," Handel said. "Of course, that did happen and it can happen. But this is very unusual."

See the original post:
2 newborns sickened by tick bites could signal an increase in infections among babies - CNN

Read the Rest...

Here’s what you need to know about superbugs in the ‘post-antibiotic era’ – Vancouver Sun

§ November 26th, 2019 § Filed under Nano Medicine Comments Off on Here’s what you need to know about superbugs in the ‘post-antibiotic era’ – Vancouver Sun

By Danielle Edwards

Antibiotics are considered one of the greatest breakthroughs in modern medicine. But in the United States, 35,000 people die a year after succumbing to germs that have evolved the ability to fend off the drugs designed to kill them. Its why two reports from the Centres for Disease Control (CDC) and an expert panel commissioned by the Council of Canadian Academies (CCA) have rung the alarm on antibiotic resistance, saying that millions of lives worldwide are at risk. Heres what you need to know about the rise of superbugs and why some experts are calling it the worlds deadliest health crisis.

How are antibiotics made?

Antibiotics are actually created naturally by bacteria to kill off neighbouring predatory organisms in an ecosystem.

In fact, Alexander Fleming made his world-changing discovery of penicillin in 1928 after observing a type of mould had antibiotic properties.

Scientists would go on to harvest soil samples to isolate more germ-killing medicine from microbes that organically evolved defence mechanisms.

Brett Finlay, a microbiology professor at the University of British Columbia, said its a simple process of natural selection.

When you put a selection pressure on any microbe, a small number of them are going to figure out how to avoid it if they can, he said.

Finlay, who sat as the chair for the CCA panel, added that microbes could evolve to reinforce their outer shells. The problem, he said, starts when those resistant microbes start to multiply.

Whats causes antibiotic resistance?

Mass antibiotic use started in earnest during the Second World War, and with large-scale usage came faster resistance rates. Finlay explained that, unlike humans, bacteria can much more effectively swap genetic information.

Once you have a resistance gene, which then resists these antibiotics in the population, it then spreads from microbe to microbe quite easily, he said.

The drugs are now used in several sectors. Though the CCA report stressed there was no one area to blame, it did list factors that have contributed to the weakening of antibiotic treatments.

The CDC estimates doctors prescribe 47 million courses of antibiotics yearly for infections that dont need them in the U.S.

The bulk of antibiotics in Canada 78 per cent are used in the production of livestock, some of them the same drugs used to treat human pathogens, which ups the chances of those germs developing resistance, as well.

Whats the worst-case scenario?

Both the reports warn of the wide-reaching effects of antibiotic resistance, like lower food production, increased hospital costs and the onset of millions of infections with no way to treat them.

Stop referring to a coming post-antibiotic era its already here, CDC Director Robert Redfield said in a letter accompanying the organizations report. You and I are living in a time when some miracle drugs no longer perform miracles and families are being ripped apart by a microscopic enemy.

Bacteria that cause illnesses like urinary tract infections and gonorrhea are some of the microbes researchers are most concerned about, especially since its becoming nearly impossible to develop new antibiotics, Finlay said.

Financial and scientific obstacles meant that no new major classes of antibiotics were approved to treat infections between 1962 and 2000.

In 2018, 26 per cent of diagnosed infections in Canada required further treatment and that number could jump to 40 per cent by 2050.

While the CDC said the number of infection-related deaths has decreased since it released a 2013 report on the resistance phenomenon, more than 2.8 million antibiotic-resistant infections are diagnosed in the U.S. every year.

There could be an enormous economic cost, as well. The CCA report projected the phenomenon could reduce Canadas GDP by up to $21 billion per year and rack up $8 billion in healthcare costs over the next thirty years.

Mitigation efforts?

Fighting antibiotics with antibiotics isnt the answer, the reports note. But they both say infection prevention, which includes good old handwashing, is one of the best ways to cut down on antibiotic use. Fewer infections means less need to prescribe the germ-killing drugs.

And medical innovations, like phage therapy which uses viruses to kill bacteria, could mean the end of our dependence on antibiotics.

Finlay said one of the biggest ways to slow the increase in resistance is stewardship making sure antibiotics are only used when theyre absolutely necessary.

You dont need antibiotic-containing detergents (that) youre using on your countertops to clean them. You dont have to use hand sanitizer every time you go out the door, he said.

Its not all bad news. There have been government efforts to lower antibiotic use (Health Canada announced last year the drugs could only be used for livestock with a valid prescription), but Finlay said it will take combined efforts from the healthcare sector and governments to take on the threat.

Its going to affect everyone, no one is immune from this, said Finlay. Whatever station in life you are, you get infections, and you need antibiotics. And if theyre not there, you suffer.

More:
Here's what you need to know about superbugs in the 'post-antibiotic era' - Vancouver Sun

Read the Rest...

Newly Published Research Shows that Hologic’s Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods – Business Wire

§ November 26th, 2019 § Filed under Nano Medicine Comments Off on Newly Published Research Shows that Hologic’s Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods – Business Wire

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection of vaginitis has been published online in the Journal of Clinical Microbiology. The prospective, multi-center clinical study is the first in the United States to formally validate the performance of the Aptima BV and Aptima CV/TV assays, available from Hologic, Inc. (Nasdaq: HOLX) on its fully automated Panther system.

Vaginitis, a condition that affects millions of women every year, is responsible for up to half of all gynecologic visits in the United States, as well as significant expense to the healthcare system.1

As leaders in womens health, we delivered on the need for new, molecular assays for vaginitis that have higher sensitivity and specificity than traditional methods, said Kevin Thornal, Hologics division president, Diagnostic Solutions. This study demonstrates that our assays are better at diagnosing infection than previously available options, which ultimately will ensure women receive the right treatment sooner.

The study notes that women suffering from vaginitis are often underserved by the current paradigm of inaccurate or incomplete diagnosis guiding inadequate or inappropriate treatment. Prior to the introduction of molecular assays, clinicians had no choice but to analyze fresh vaginal discharge samples using a combination of older, subjective methods pH, a potassium hydroxide (KOH) whiff test and Gram-stained microscopic examination to identify the underlying cause.

The new Aptima molecular tests circumvent barriers to accurate diagnosis associated with the use of these traditional methods, including absence of proper equipment, lack of training, and access to microscopy in the clinic. These and other barriers can result in many women being misdiagnosed, which the study says can lead to incorrect, misguided or prolonged treatment.1 In fact, separate research shows that when treatment is based on diagnosis with these traditional methods, more than half of women with vaginitis experience recurring symptoms.2

Many women try to self-diagnose and self-treat before eventually visiting a healthcare provider, assuming that abnormal vaginal discharge, itching or irritation is due to a simple yeast infection, said the studys corresponding author, Dr. Jane R. Schwebke, professor of medicine at the University of Alabama at Birmingham. But BV or TV left untreated or improperly treated can put women at risk for a variety of complications, including an increased chance of getting sexually transmitted infections (STIs) such as chlamydia or HIV, pelvic inflammatory disease, and pregnancy-related risks including premature delivery, low birth weight and infertility.2,4 These objective and comprehensive diagnostic tests will mitigate such risks and allow clinicians to feel more confident that theyre properly treating women.

BV (bacterial vaginosis) is the most common vaginal infection in the U.S., affecting an estimated 21 million women a year.3 Together with CV (vulvovaginal candidiasis) commonly known as yeast infections and TV (trichomonas vaginalis), individually or in combination, these three vaginal infections cause about 90 percent of vaginitis infections.2,4 Each cause of vaginitis has its own characteristics, consequences and treatment recommendations, which vary between BV, CV and TV, further reinforcing the need for accurate diagnoses.

Study Details

Subjects in the multi-center, cross-sectional diagnostic accuracy study for the Aptima BV and Aptima CV/TV assays were at least 14 years old with symptoms of vaginitis such as abnormal vaginal discharge, vaginal odor, genital itching or irritation, pain or discomfort during sexual intercourse or urination, edema or erythema. They were enrolled at 21 U.S. sites, including clinical research centers and emergency medicine, family planning, public health, STI and family medicine/obstetric-gynecologic (OB-GYN) facilities between June and October 2018.

Patient- and clinician-collected vaginal swab samples obtained from women with symptoms of vaginitis were tested with the Aptima BV and Aptima CV/TV assays. The prevalence of infection was similar for clinician- and patient-collected samples: 49 percent for BV, 29 percent for CV due to the Candida species group, 4 percent for CV due to C. glabrata, and 10 percent for TV. Sensitivity and specificity estimates for the tests in clinician-collected samples were, respectively, 95.0 percent and 89.6 percent for BV, 91.7 percent and 85.8 percent for the Candida species group, 84.7 percent and 99.1 percent for C. glabrata, and 96.5 percent and 98.9 percent for TV. Sensitivity and specificity were similar in patient-collected samples.

Hologic offers 16 FDA-cleared assays on the Panther system that detect more than 20 pathogens, offering the only high-throughput molecular diagnostic platform in the U.S. to combine comprehensive sexual health, cervical health, viral load, respiratory testing and open channel functionality on a fully automated system.

For more information on the Aptima BV and Aptima CV/TV assays, visit http://www.hologic.com.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving womens health and well-being through early detection and treatment. For more information on Hologic, visit http://www.hologic.com.

Hologic Forward-Looking Statements

This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologics diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, Aptima, Panther and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Source: Hologic, Inc.

____________________

More:
Newly Published Research Shows that Hologic's Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods - Business Wire

Read the Rest...

Eight Illinois faculty members elected AAAS Fellows | Illinois – University of Illinois News

§ November 26th, 2019 § Filed under Nano Medicine Comments Off on Eight Illinois faculty members elected AAAS Fellows | Illinois – University of Illinois News

CHAMPAIGN, Ill. Eight professors at the University of Illinois at Urbana-Champaign have been elected 2019 Fellows of the American Association for the Advancement of Science.

Plant biology professor and researcher Elizabeth Lisa Ainsworth; mechanical science and engineering professor Andrew Alleyne; materials science and engineering professor David Cahill; chemistry professor Paul Hergenrother; evolution, ecology and behavior professor Andrew Suarez; and computer science professors Sheldon Jacobson, Klara Nahrstedt and Tao Xie are among the 443 people to be awarded the distinction of AAAS Fellow this year.

Elizabeth "Lisa" Ainsworth

Photo by L. Brian Stauffer

Edit embedded media in the Files Tab and re-insert as needed.

Ainsworth is the research leader of the U.S. Department of Agriculture Agricultural Research Service Global Change and Photosynthesis Research Unit. Her research examines genetic variation in crop responses to air pollution and climate change. A key goal of her work is to maximize crop production in the future. She was the 2019 recipient of the National Academy of Sciences Prize in Food and Agricultural Research and a 2018 recipient of the Presidential Award from the Crop Sciences Society of America. She also is affiliated with the Carl R. Woese Institute for Genomic Biology at the U. of I.

Alleyne is a Ralph and Catherine Fisher Professor of Engineering and is recognized for his contributions to the theory and practice of automatic control. His expertise spans precision motion control for advanced manufacturing as well as control of transient thermal systems. He is currently tackling the thermal and electrical challenges surrounding electrified mobility through the National Science Foundation Engineering Research Center on Power Optimization for Electro Thermal Systems. He is a fellow of the American Society of Mechanical Engineers and the Institute for Electrical and Electronic Engineers. He serves on the U.S. Air Force Scientific Advisory Board and the National Academies Board on Army Research and Development.

David Cahill

Photo by L. Brian Stauffer

Edit embedded media in the Files Tab and re-insert as needed.

Cahill is a Willett Professor of Engineering and was the department head of materials science and engineering from 2010-18. He is an expert on the concept of minimum thermal conductivity and transient optical measurement techniques. His research program focuses on developing a microscopic understanding of thermal transport at the nanoscale; the discovery of materials with enhanced thermal function; the interactions between phonons, electrons, photons and spin; and advancing fundamental understanding of interfaces between materials and water. Cahill is an American Physical Society fellow and received the 2018 Innovation in Materials Characterization Award of the Materials Research Society.

Paul Hergenrother

Photo by L. Brian Stauffer

Edit embedded media in the Files Tab and re-insert as needed.

Hergenrother is an expert in the molecular basis of disease and has distinguished himself by translating his most promising discoveries into real-world applications. He has made advances in the way new medicines are discovered and developed, using readily available natural products as the starting point for complex molecule synthesis. His discoveries impact not only basic scientific research but also the lives of cancer patients. Hergenrother received the 2017 American Chemical Society Sosnovsky Award for Cancer research. He also is affiliated with the IGB and the Carle Illinois College of Medicine at the U. of I.

Sheldon Jacobson

Photo by L. Brian Stauffer

Edit embedded media in the Files Tab and re-insert as needed.

Jacobson, a Founder Professor in Computer Science, applies his expertise in operations research and data science to topics that inform public policy. His research has produced data-driven analysis of elections, political redistricting, pediatric vaccines, cellphone use while driving, mass killing trends, and links between obesity and transportation. His seminal work on risk-based security provided the technical foundations that informed the design of TSA PreCheck. He also is known nationally for his work on bracketology the analysis of the NCAA mens basketball tournament and created the BracketOdds website. He received a Guggenheim Fellowship in 2003. He also is affiliated with the Carle Illinois College of Medicine.

Klara Nahrstedt

Photo by L. Brian Stauffer

Edit embedded media in the Files Tab and re-insert as needed.

Nahrstedt, the Ralph and Catherine Fisher Professor of Computer Science and director of the Coordinated Science Laboratory, is an expert in multimedia systems and networks. Her expertise in dynamic soft-real-time CPU scheduling and energy-efficient operating systems for mobile multimedia devices is widely recognized in academia and industry. She is a member of the Academy of Sciences in Germany and belongs to the Excellence Commission appointed by the Joint Science Conference of the German Federal Government. Nahrstedt received the 2019 Drucker Award from the Grainger College of Engineering and also is affiliated with the Beckman Institute for Advanced Science and Technology at the U. of I. and the Carle Illinois College of Medicine.

Andrew Suarez

Photo by L. Brian Stauffer

Edit embedded media in the Files Tab and re-insert as needed.

Suarez, a professor of entomology and head of the department of evolution, ecology and behavior, is a leading figure in conservation and invasion biology. He is an expert on introduced ants, especially the globally invasive Argentine ant, Linepithema humile. His research on native populations of invasive species demonstrated the utility of a biogeographic approach to understanding invasion success, pioneering an approach that is considered the gold standard in the field. He also conducts research on trap-jaw ants, whose mandibles are among the fastest biological movements. Suarez is a recipient of the 2017 University of Illinois Campus Award for Excellence in Undergraduate Teaching. He also is affiliated with the IGB.

Tao Xie

Photo by L. Brian Stauffer

Edit embedded media in the Files Tab and re-insert as needed.

Xie is a Willett Faculty Scholar. His work in software engineering focuses on software testing, analytics and security; the intersection between software engineering and artificial intelligence; and educational software engineering. His expertise in these areas has earned him many honors, including being elected an Institute of Electrical and Electronics Engineers Fellow in 2018 and an Association for Computing Machinery Distinguished Scientist in 2015.

Founded in 1848, AAAS is the worlds largest general scientific society. Fellows are chosen by their peers for outstanding contribution to the field. The new Fellows will be honored at the 2020 AAAS annual meeting in Washington, D.C.

Continued here:
Eight Illinois faculty members elected AAAS Fellows | Illinois - University of Illinois News

Read the Rest...

Father bedbound by Lyme disease is back on his feet due to a drug for alcoholism Yahoo Lifestyle – X Herald

§ November 26th, 2019 § Filed under Nano Medicine Comments Off on Father bedbound by Lyme disease is back on his feet due to a drug for alcoholism Yahoo Lifestyle – X Herald

Ciaran Hughes, 31, created steady torment, worked development and lost equalization in March.

A dad who was bedbound by Lyme ailment is at long last in a good place again because of a medication for liquor abuse.

Ciaran Hughes, 31, created consistent torment, toiled development and lost equalization in March while working in Indonesia.

Numerous tests both abroad and in his local Northern Ireland returned clear, including one for Lyme ailment.

Peruse MORE:Lyme ailment cases triple higher than recently evaluated

Urgent, Mr Hughes looked for private treatment. In spite of the fact that this prompted his determination, the recommended anti-infection agents neglected to facilitate his indications.

The dad of-two chose to bring matters into his very own hands. While investigating on the web, he went over a specialist in the US who treats patients with the liquor reliance tranquilize disulfiram.

Since forking out 66 for the medicine a month ago, Mr Hughes as of now feels more splendid and like an appropriate father to his young men once more.

In a good place again, Mr Hughes feels like a legitimate father to his children, matured seven and four months. [Photo: Supplied]

More

Mr Hughes, who works for a seaward oil organization, started to feel unwell 10 days after he accepts he was nibbled.

I was in steady agony, he revealed to Yahoo UK. My body felt overwhelming, my developments were exceptionally toiled and I lost my feeling of equalization.

Mr Hughes was tried for Lyme sickness while in Indonesia, which gave no indications for concern.

We cannot theorize why the test returned negative, Mr Hughes private surgeon Dr Josh Berkowitz, from theLyme Disease Clinic, disclosed to Yahoo UK.

It might be it was not done appropriately or it could be the Lyme contamination hadnt set off the insusceptible framework reaction adequately around then.

At the point when you test for a disease you are searching for the insusceptible framework response and markers, not simply the bug.

The Lyme living being is known to be great at stowing away and not provoking an insusceptible framework reaction, along these lines tests can return negative.

When home, Mr Hughes was alluded by his GP to a cardiologist when he created chest torment.

With tests again returning clear, things before long got ugly.

I was enduring nerve torment, deadness in my grasp, sticks and needles, fits in my arms and legs, and extremely solid migraines, Mr Hughes said.

Demanding something was genuinely off-base, he was alluded to a nervous system specialist, who again gave him the all-unmistakable.

To err on the side of caution, Mr Hughes was recommended anti-infection agents, in any case, the medications did little to facilitate his misery.

I was bedbound and incapable to do the least difficult undertakings, he said.

I lost enthusiasm for things around me, couldnt center or concentrate for any time allotment and was totally depleted.

Peruse MORE:What are the signs and indications of Lyme infection?

Persuaded he may have Lyme infection, Mr Hughes looked for private treatment at the Lyme Disease Clinic in August.

At this point his resistant framework had reacted to the contamination and delivered surrogate markers as a response to the disease, Dr Berkowitz said.

The surgeon recommended anti-toxins, which helped to some degree.

Persuaded a progressively powerful treatment was out there, Mr Hughes went over crafted by Dr Ken Liegner in New York.

I read preliminaries of disulfiram being utilized to treat Lyme malady are in the beginning periods and it doesnt work for everybody, Mr Hughes said.

Be that as it may, many patients are feeling better on it and I needed to give it a go.

Dr Berkowitz consented to endorse a low-portion of the medication, which is step by step being expanded.

Mr Hughes paid 66 for 100 tablets, which are relied upon to most recent two months.

Sick be straightforward, two days subsequent to increasing the portion I feel terrifying once more, as a greater amount of the illness in my body ceases to exist, he said.

In any case, at that point I return feeling good and more grounded each time.

Albeit still too sick to even think about working, Mr Hughes is no longer bedbound or pondering steady torment.

I feel more brilliant, my contemplations are clear, my vitality is returning, and Im physically functional at home, he said. I at long last feel like an appropriate father again to my young men.

To screen his advancement, Mr Hughes has blood, liver and kidney tests like clockwork, which are so far returning clear.

Not all patients build up the obvious pinpoint center rash around the tick nibble. [Photo: Getty]

More

Lyme infection isnt normal in the UK, influencing 2,000 to 3,000 individuals consistently in England and Wales,government insights appear.

Furthermore, in the US, around 30,000 cases arereported to the Centers for Disease Control and Prevention every year.

Manifestations will in general be dubious and influenza like, including exhaustion, fever and chills.

Also, not all build up the obvious bulls eye rash around the bite,Dr Paul Taylor, of Sunnybrook Hospital in California, composed on YourHealthMatters.

A postponement in conclusion can enable the microorganisms to penetrate nerve cells, the cerebrum, different organs, collagen and connective tissue, making it difficult to cleanse from the body, he included.

The persistent pathogen regularly likewise creates protection from anti-infection agents, with long periods of treatment being required.

Disulfiram was first proposed as a possibility for Lyme illness after the screening of 7,450 medication atoms recommended it was exceptionally dynamic against the microorganisms in the research center.

Dr Liegner treated three patients with backsliding contaminations with the medication, which at first disposed of the requirement for further antimicrobial treatment in two of them.

One proceeded to backslide, in any case, and required further treatment.

Albeit indistinct, Dr Liegner estimates disulfiram may influence microbial surface film adaptability and capacity.

It has additionally been appeared to have hostile to parasitic movement in the research center.

Peruse MORE:Can Lyme illness truly cause you to lose your voice?

I am mindfully hopeful about disulfiram, Dr Berkowitz said. It ought to be endorsed with incredible consideration and given to patients couple with the acknowledged conventions for treating Lyme ailment.

The NHS expresses a course of anti-infection agents is the go-to treatment for Lyme illness.

[Disulfiram] is certainly not a silver shot for the malady however it could demonstrate supportive in accelerating the recuperation of certain patients and boosting the advancement among those leveling in their treatment out of the blue, Dr Berkowitz said.

We realize disulfiram is a protected and endorsed medicate for liquor addiction yet need to get familiar with how and why it could assist individuals with battling Lyme malady.

Another hypothesis is the medication particle is littler than the anti-infection agents used to treat Lyme malady.

It might have the option to assault the microorganisms in tissues and cells at a more profound level, accordingly speeding recuperation, Dr Berkowitz said.

In contrast to anti-toxins, disulfiram can likewise infiltrate biofilms, which emerge when microscopic organisms put down roots on a surface.

This may empower the liquor abuse medication to arrive at microorganisms not open to anti-infection agents.

With regards to Lyme malady, Dr Berkowitz stresses anticipation is superior to fix. With no vaccine,Public Health England (PHE) claimsthe most ideal approach to maintain a strategic distance from disease is to evade ticks.

It prescribes strolling on obviously characterized ways and abstaining from brushing against vegetation whenever the situation allows.

PHE likewise exhorts wearing light attire to help detect any slithering ticks.

A creepy crawly repellent may help demoralize ticks, while long pants and sleeves can lessen the measure of uncovered skin the ticks could join to.

In the event that you detect a tick, utilize fine-tipped tweezers or a tick evacuation device, PHE prescribes.

Handle the bug as near the skin as could reasonably be expected, pulling upwards gradually and solidly.

Dr Berkowitz additionally suggests checking your pets for ticks after they have been outside.

Read more:
Father bedbound by Lyme disease is back on his feet due to a drug for alcoholism Yahoo Lifestyle - X Herald

Read the Rest...

Global Nanomedicine Market 2019 GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc. – The…

§ November 26th, 2019 § Filed under Nano Medicine Comments Off on Global Nanomedicine Market 2019 GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc. – The…

The Nanomedicine report delivers a comprehensive and systematic framework of the worldwide Nanomedicine Market at a global level that includes all the key aspects related to it. The data is collected from different sources allied to the Nanomedicine and the research team meticulously analyze the gathered data with the help of various analytically tools and present their opinion based on analysis and calculations.

The Global Nanomedicine Market 2019 report offers clear-cut information about the key business-giants GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., Smith & Nephew PLC, Stryker Corp, Teva Pharmaceutical Industries Ltd., UCB (Union chimique belge) S.A challenging with each other in the worldwide Nanomedicine in terms of demand, sales, revenue generation, reliable products development, giving best services, and also post-sale processes at the global level.

To Get Free Sample Copy of Report Click Here: http://www.mrsresearchgroup.com/report/170399#request-sample

This Global Nanomedicine Market 2019 report is integrated with primary as well as secondary research of the Global industry. The worldwide Nanomedicine in detail and presents comprehensive forecasts regarding the markets growth trajectory during the forecast period (2019 2025)

The Global Nanomedicine Market 2019 report is based on key players, which are combined by market share, history of growth and Industry forecasts, it provides in-detailed information, basic needs of the market, and the report shows the how this market is growing Globally. The main regions that contribute to the worldwide Nanomedicine Market 2019 are United States, Europe, Japan, China, India, Southeast Asia.

This report holds each and every aspect of the international market for this specific domain, ranging from the primary market data to many important criteria, based on which, the worldwide Nanomedicine is standardized. The main functioning domains of the Nanomedicine are also covered based on their performance.

Request For Free Price Quotation @ http://www.mrsresearchgroup.com/report/170399#inquiry-for-buying

There are 15 Chapters to display the Global Nanomedicine Market 2019

Chapter 1, to describe worldwide Nanomedicine Market 2019 Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Nanomedicine Market 2019, with sales, revenue, and price of worldwide Nanomedicine, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of worldwide Nanomedicine, for each region, from 2012 to 2017;

Chapter 5, 6, 7, 8 and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;

Chapter 12, Global Nanomedicine Market 2019 forecast, by regions, type and application, with sales and revenue, from 2017 to 2022;

Chapter 13, 14 and 15, to describe Global Nanomedicine Market 2019 sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

In the end, worldwide Nanomedicine Industry 2019 report provides the main region, market conditions with the product price, profit, capacity, production, supply, demand, and market growth rate and forecast etc. This report also Present new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Sorry! The Author has not filled his profile.

Link:
Global Nanomedicine Market 2019 GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc., Nanosphere Inc., Pfizer Inc. - The...

Read the Rest...

Increasing Trend of Nanomedical Devices And Therapeutic Market to Access Huge Growth by 2019-2025 Focusing on Leading Players PerkinElmer,Arrowhead…

§ November 26th, 2019 § Filed under Nano Medicine Comments Off on Increasing Trend of Nanomedical Devices And Therapeutic Market to Access Huge Growth by 2019-2025 Focusing on Leading Players PerkinElmer,Arrowhead…

Crystal Market Research authorities conduct a triangulated approach of primary and secondary research on Global Nanomedical Devices And Therapeutic Market and carry out an in-depth analysis of multiple factors, including Nanomedical Devices And Therapeutic technological developments and the demand-supply shifts in various markets across the globe to accurately forecast the industrys growth possibilities. To assist clients to frame effective tactics for growth on global Nanomedical Devices And Therapeutic market for the period of 2019 to 2025.

It offers market insights from the statistics, gathered from reliable Nanomedical Devices And Therapeutic market informants such as manufacturers, channel partners, decision makers, and regulatory bodies. Based on various clients stipulations, Nanomedical Devices And Therapeutic also produces customized reports, which will help local vendors and global players cement their position in the chemicals and materials market.

Continue

Click Here for Get Sample Copy of this Report @https://www.crystalmarketresearch.com/report-sample/HC101499

The Nanomedical Devices And Therapeutic market outline segment of the report investigates progression, for example, drivers, limitations, and opportunities that, at present, strongly affect the market and could impact the market in future also. Nanomedical Devices And Therapeutic market share analysis has been given in the report with a particular ultimate objective to explain the power of contention between market players working over the globe.

Get it in discounted Price: https://www.crystalmarketresearch.com/check-discount/HC101499

Get Customized Research Report: https://www.crystalmarketresearch.com/customization/HC101499

Contacts Us:

Judy | 304 South Jones Blvd, Suite 1896

Las Vegas NV 89107

United States

E-mail: sales@crystalmarketresearch.com | Ph: +1-888-213-4282

More:
Increasing Trend of Nanomedical Devices And Therapeutic Market to Access Huge Growth by 2019-2025 Focusing on Leading Players PerkinElmer,Arrowhead...

Read the Rest...

Nanomedical Market Changing Market Trends, New Business Opportunities Analysis and Forecast with Revenue Growth 2019-2025 – Markets Gazette 24

§ November 26th, 2019 § Filed under Nano Medicine Comments Off on Nanomedical Market Changing Market Trends, New Business Opportunities Analysis and Forecast with Revenue Growth 2019-2025 – Markets Gazette 24

New York, November 26, 2019: The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Nanomedical market share. Major industry players with significant revenue share include Johnson & Johnson, Mallinckrodt plc., Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, CombiMatrix Corporation, General electric Company, Sigma-Tau Pharmaceuticals, Inc., and others.

The Nanomedical Market is expected to exceed more than US$ 306 Billion by 2024 at a CAGR of 10.3% in the given forecast period.

Browse Full Report: https://www.marketresearchengine.com/nanomedical-market

Nanomedicine market is mainly driven by increase in acceptance of nanomedicine across diverse applications, rise in government funding & support, emerging technologies for drug delivery, rise in need for therapies with less side effects and allergies, and cost-effectiveness of therapies.

Growing healthcare facilities in developing countries are anticipated to bring numerous opportunities for the growth of nanomedicine market.

Nanomedicine is one of the applications of nanotechnology used in treatment, monitoring, diagnosis, and control of biological systems. Nanomedicine utilizes nanoscale control of materials to improve medicine delivery. Subsequently, nanomedicine has encouraged treatment against different diseases.

The global Nanomedical market is segregated on the basis of Indication as Ophthalmological Diseases, Immunological Diseases, Cardiovascular Diseases, Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Neurological Diseases, Urological Diseases, and Others. Based on Application the global Nanomedical market is segmented in Implants, Regenerative Medicine, Diagnostic Imaging, Drug Delivery, Vaccines, and Others. Based on Modality the global Nanomedical market is segmented in Treatments and Diagnostics.

The global Nanomedical market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Nanomedical market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

Johnson & Johnson, Mallinckrodt plc., Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, CombiMatrix Corporation, General electric Company, Sigma-Tau Pharmaceuticals, Inc., and others are among the major players in the global Nanomedical market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Nanomedical Market has been segmented as below:

The Nanomedical Market is segmented on the lines of Nanomedical Market, By Indication, Nanomedical Market, By Application, Nanomedical Market, By Modality, Nanomedical Market, By Region and Nanomedical Market, By Company.

Nanomedical Market, By Indication this market is segmented on the basis of Ophthalmological Diseases, Immunological Diseases, Cardiovascular Diseases, Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Neurological Diseases, Urological Diseases and Others. Nanomedical Market, By Application this market is segmented on the basis of Implants, Regenerative Medicine, Diagnostic Imaging, Drug Delivery, Vaccines and Others. Nanomedical Market, By Modality this market is segmented on the basis of Treatments and Diagnostics. Nanomedical Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Nanomedical Market, By Company this market is segmented on the basis of Johnson & Johnson, Mallinckrodt plc., Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Abbott Laboratories, CombiMatrix Corporation, General electric Company and Sigma-Tau Pharmaceuticals, Inc.

The report covers:

Report Scope:

The global Nanomedical market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/nanomedical-market

Table of Contents:

Other Related Market Research Reports:

Biologic and Medical Imaging Reagents Market Overview and Share Forecasted to 2024 MRE Report

Hospital Supplies Market 2019 Perceive Substantial Growth During 2024 MRE Report

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: john@marketresearchengine.com

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

See the original post here:
Nanomedical Market Changing Market Trends, New Business Opportunities Analysis and Forecast with Revenue Growth 2019-2025 - Markets Gazette 24

Read the Rest...

Global Nanomedicine Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2024 – The Chicago Sentinel

§ November 25th, 2019 § Filed under Nano Medicine Comments Off on Global Nanomedicine Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2024 – The Chicago Sentinel

MarketandResearch.bizhas recently announced the addition of new research report to its repository named,GlobalNanomedicine Market Research 2019 by Manufacturers, Regions, Countries, Types and Applications, Forecast to 2024. It provides a clear understanding of the market dynamics by studying the historical data and analyzing the current market situation. It aims to chalk the route of the market for the coming few years. It gives a comprehensive synopsis of the market picture including market overview, introduction, classification, market dynamics,and market size.

DOWNLOAD FREE SAMPLE REPORT:https://marketandresearch.biz/sample-request/85199

TheNanomedicinemarket research report includes a separate section which specifies key players profiles allowing understanding the pricing structure, cost,Nanomedicinecompany basic information, their contact details,and product category.

Main leading players in theNanomedicineMarket Are:, Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences, ,

GlobalNanomedicinehas witnessed gradual growth in recent years and is expected to witness steady growth in the forecast period.In this report, theNanomedicinemarket is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2024, growing at a CAGR of XX% between 2019 and 2024.

TheNanomedicinereport contains brief information on these trends that can help the businesses operating in the industry to know constituents of the market and strategize for their business expansion accordingly. Moreover, various rudimentary aspects of theNanomedicinemarket such as market size, industry share, growth, key segments, and CAGR are also added in the report. The next section of the report serves detailed overview ofNanomedicineproduct specification, product type, product scope, and production analysis with key factors such as capacity, production, revenue, price and gross margin.

The notable feature of this report is that it presents an all-enclosing view of theNanomedicinemarket based on its segmentation, with respect to types, application, end-users, products, and geography.

The report executes the great study of capacity, production, revenue, price, gross margin, technology, demand-supply, consumption, import, export, market drivers and opportunities.It also discusseslimitations, risks, and challenges which will decide the standing future of the market all over the world.

The Study Report Provides In-depth Analysis On:

ACCESS FULL REPORT:https://marketandresearch.biz/report/85199/global-nanomedicine-industry-market-research-2019-by-manufacturers-regions-countries-types-and-applications-forecast-to-2024

Furthermore, manufacturing cost structure combines analysis of key raw materials, their price trends along with labor cost and manufacturing expenses. For market chain analysis, the report covers upstream raw materials, equipment, downstream buyers, marketing channels, and market development trend which more deeply include important information on key distributors/traders, major raw materials suppliers and contact information, major manufacturing equipment suppliers, major suppliers, and key consumers.

The report profiles SWOT analysis and market strategies of the key players. Any individual or organization interested in the report can greatly benefit from it. The market research data added in the study is the result of extensive primary and secondary research activities, surveys, personal interviews, and inputs from industry expert.

See more here:
Global Nanomedicine Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2024 - The Chicago Sentinel

Read the Rest...

Global Healthcare Nanotechnology Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – Industry News Time 24

§ November 25th, 2019 § Filed under Nano Medicine Comments Off on Global Healthcare Nanotechnology Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – Industry News Time 24

A profound analysis of the industry based on the "Healthcare Nanotechnology Market" all over the world is named as Global Healthcare Nanotechnology Market Report. The research report assesses the current as well as the upcoming performance of the Healthcare Nanotechnology market, in addition to with newest trends in the market. The major player of the Healthcare Nanotechnology market (Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International)are also included in the market report. The report forecasts the future of the Healthcare Nanotechnology market on the basis of this evaluation.

The research analysis for Healthcare Nanotechnology market comprises each and every feature of the market all over the world, which starts from the Healthcare Nanotechnology market description and ends on the Healthcare Nanotechnology market segmentation (Nanomedicine, Nano Medical Devices, Nano Diagnosis, Other). In addition to this, each section of the Healthcare Nanotechnology market is categorized and evaluated on the basis of goods, the end-user clients of the Healthcare Nanotechnology market, and the employment of the products. The geographical categorization of the Healthcare Nanotechnology market (Anticancer, CNS Product, Anti-infective, Other) has also been evaluated thoroughly in the report.

Ask for sample link here: https://www.intenseresearch.com/market-analysis/global-healthcare-nanotechnology-market-2019-by-manufacturers-countries.html#request-sample

The Healthcare Nanotechnology perusers will discover this report exceptionally advantageous in the comprehension of the Healthcare Nanotechnology showcase in the nitty-gritty. The angles and data are spoken to in the Healthcare Nanotechnology report utilizing figures, structured presentations, pie graphs, and other visual portrayals. This escalates the Healthcare Nanotechnology pictorial portrayal and furthermore helps in getting the Healthcare Nanotechnology business actualities much better. The Healthcare Nanotechnology advertise is probably going to develop at a noteworthy CAGR. The principle goal of the Healthcare Nanotechnology report is to direct the client to comprehend the Healthcare Nanotechnology advertise as far as its definition, order, Healthcare Nanotechnology showcase potential, most recent patterns, and the difficulties that the Healthcare Nanotechnology advertises is confronting.

Questions replied in this Healthcare Nanotechnology report: https://www.intenseresearch.com/market-analysis/global-healthcare-nanotechnology-market-2019-by-manufacturers-countries.html

1. What will the Healthcare Nanotechnology advertise projection and what will the advancement rate by 2024?

2. What are the major Healthcare Nanotechnology advertise designs?

3. What is the development of driving components of the Healthcare Nanotechnology industry?

4. What are the snags being developed to the Healthcare Nanotechnology showcase?

5. Who are the Healthcare Nanotechnology driving sellers in a market?

6. What are the market space and limitations by the Healthcare Nanotechnology key sellers?

7. What are the Healthcare Nanotechnology driving sellers quality through SWOT and PESTEL consider?

Another area of the Healthcare Nanotechnology advertise report uncovers the procedure of creation. Be that as it may, this procedure gauges nitty-gritty Healthcare Nanotechnology think about with respect to assembling cost which incorporates crude stock, and diverse providers for modern offices.

Enquire about our report with our industry authority:

Overall Healthcare Nanotechnology Market Report Importance:

Our report significantly fixates around genuine research on each part and its general result on the Healthcare Nanotechnology showcase advance.

The objective gathering of watchers of the Healthcare Nanotechnology report acclimatizes new wannabes planning to wind up an expansive comprehension of the business, masters, monetary establishments, real accomplices, profitability, Healthcare Nanotechnology wholesalers, and industry organization.

To get the examination techniques those are being gathered by Healthcare Nanotechnology driving individual associations.

To have the misgiving without obstacles Healthcare Nanotechnology stance and a probability for the market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.

About Us Market and Research are a trusted brand in the research industry with the capability of commissioning complex projects within a short span of time with a high level of accuracy. At Market and Research, we believe in building long term relations with our clients. Our services cover a broad spectrum of industries including Energy, Chemicals and Materials, Automotive and Aerospace.

Contact Us: Market and Research United States

Sorry! The Author has not filled his profile.

See original here:
Global Healthcare Nanotechnology Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - Industry News Time 24

Read the Rest...

Stanford postdoc and students cited as example to girls interested in STEM fields | The Dish – Stanford University News

§ November 25th, 2019 § Filed under Nano Medicine Comments Off on Stanford postdoc and students cited as example to girls interested in STEM fields | The Dish – Stanford University News

by Alex Kekauoha on November 24, 2019 10:31 am

Dorothy Tovar, PhD student in microbiology and immunology, is among those selected to be an IF/THEN ambassador. (Courtesy Dorothy Tovar)

Three Stanford students and one postdoctoral scholar have been selected to the first class of IF/THEN ambassadors for the American Association for the Advancement of Science. Each will provide support and mentorship to young girls interested in pursuing STEM fields.

Catie Cuan

Graduate students CATIE CUAN and DOROTHY TOVAR, postdoctoral scholar HELEN TRAN and undergraduate ERIN SMITHare among 125 women selected to serve as ambassadors.

The ambassadors recently attended the IF/THEN Summit in Dallas, Texas, where they participated in a full-body scan that produced life-sized 3D-printed statues of the ambassadors the largest collection of statues of women. Ambassadors will also work with Bay Area Girl Scout troops, appear on the network television series Mission Unstoppable about women working on cutting-edge STEM projects and participate in media campaigns.

The IF/THEN initiative is based on the idea that if women in STEM fields are supported, then they can change the world. The program is supported by a $25 million commitment from Dallas-based Lyda Hill Philanthropies. It is also a partnership with the American Association for the Advancement of Science, which works to advance science, engineering and innovation throughout the world for the benefit of all people.

Catie Cuan is a PhD candidate in the Department of Mechanical Engineering. Growing up in Berkeley, California, she loved math and science, but had few female role models in those fields.

Helen Tran

This resulted in a self-imposed narrowing of what my future possibilities were, she said.

Cuan earned a bachelors degree from the University of California, Berkeley, and has had a career as a dancer and choreographer. After making performances and art installations with robots, she decided to pursue a graduate degree in mechanical engineering.Cuan is currently designing physical interactions between humans and robots, as well as haptic devices to tele-operate robots.

Helen Tran is the Intelligence Community postdoctoral fellow in the lab of Professor Zhenan Bao in the Department of Chemical Engineering.

A native of San Jose, California, science was not on Trans radar until college. She earned a bachelors degree in chemistry from the University of California, Berkeley, and a PhD in chemistry from Columbia University. She joined Stanford in 2016 and is currently researching biodegradable stretchable electronics.

Through the IF/THEN program, Tran has enjoyed learning about the quantitative studies on the importance of media representation of women in media.

Dorothy Tovar is a PhD student studying microbiology and immunology.

Erin Smith

Growing up in Cambridge, Massachusetts, Tovar became interested in science at a young age. She frequently read science books and encyclopedias and watched countless hours of the Discovery Channel. She also spent some of her childhood in Haiti, where she became fascinated by the way microscopic organisms could cause diseases that devastate entire countries.

Tovar earned a BS in microbiology from the University of Massachusetts, Amherst, where she was awarded the universitys 21st Century Leader Award. She joined Stanford Medicine in 2015.

Erin Smith, a first-year student and native of Kansas, is the founder ofFacePrint, an AI tool to detect and monitor Parkinsons disease and commonly misidentified neurological disorders using video technology and early-stage facial expression indicators. She is currently off campus pursuing a Thiel Internship.

Smiths research interest was spurred when she watched a video by the Michael J. Fox Foundation and noticed that Parkinsons patients smiles and laughter often appeared emotionally distant years before diagnosis. She talked to clinicians and caretakers, who reported similar observations. As she read through past medical papers. she found that the often-overlooked parts of the brain that experience some of the earliest changes in Parkinsons patients are the same parts involved in the formation of facial expressions. Smith became captivated by the idea of using facial expressions to monitor changes in the brain like Parkinsons and objectively detect its onset.

Mentors have had a pivotal impact on my life, said Smith. I am looking forward to the opportunity to engage with young students and help shape their futures.

Read more in the Roundabout.

See original here:
Stanford postdoc and students cited as example to girls interested in STEM fields | The Dish - Stanford University News

Read the Rest...

Sorry, there’s no cure for the common cold: Opinion – CBC.ca

§ November 25th, 2019 § Filed under Nano Medicine Comments Off on Sorry, there’s no cure for the common cold: Opinion – CBC.ca

The common cold makes us feel miserable sore throat, sinus congestion, runny nose, sore or plugged ears, coughing but please don't ask for antibiotics to fix it.

Despite all of the advances in medicine the old saying remains true: there is no cure for the common cold.

Many people believe antibiotics will help end or shorten a cold. Unfortunately, that is not the case.

Infections come in different flavours, depending on what microscopic organism or bug is responsible. Two big groups of infection-causing organisms are viruses and bacteria.

Viruses and bacteria are very different. Bacteria are living, tiny, single cells that can replicate all on their own. Viruses aren't full cells. They require an actual cell (like your sinus or lung cells) to help them replicate and cause infection.

Antibiotics are drugs that stop or kill bacteria only.They prevent the bacteria from replicating: for example, by poking holes in the bacterial cell wall.

Here's the thing: colds are caused by viruses.

Viruses are so vastly different than bacteria that antibiotics do nothing to stop them or even slow them down.

Think of a balloon and a bowling ball.If you want to destroy the balloon, you could use a sharp pin.But if you want to destroy the bowling ball, your pin is useless. It's the wrong tool for the job.

While there are some antiviral medications out there (examples are HIV treatment or cold sore medication), there are none that work on the many viruses that cause colds.

The great majority of colds run their course and disappear. On occasion, however, colds can get complicated.

When your ears and lungs are plugged up with the usual mucus that comes with a cold, the bacteria that hang around your body can sometimes take advantage of their changed environment, and cause an infection of their own.

Signs that you may have developed a bacterial infection include high fever or chills, or sudden new pain in one place (your ear, chest, or a sinus).

Green or yellow mucus from your nose or chest can be from a viral or bacterial infection (the green colour comes from your own immune cells, not the bug), but a big change in the colour or amount of mucus could mean trouble.

The timeline also matters. A cold should run from five to 10 days (though sometimes the cough hangs on for a few weeks) and you should be feeling gradually better toward the end.Starting to suddenly feel worse can be a bad sign.

No single symptom or sign will confirm you have a bacterial infection.But your doctor can look at the whole picture and decide how likely it is that you might need treatment for one with antibiotics.

For people with a known lung disease like asthma or chronic obstructive pulmonary disease, the lungs aren't normal. If you have a lung disease, check with your doctor for what to do when you get chest infection symptoms.

If you are diagnosed with a bacterial infection, you'll be prescribed antibiotics. It is very important to use them properly, as instructed by your doctor and pharmacist.

These drugs aren't fail-safe. Because bacteria are living organisms, they can mutate and adapt to become better at surviving a course of antibiotics. This phenomenon is called antibiotic resistance.

Antibiotic resistance is developing faster than we can come up with new antibiotics.It is a very real and difficult problem.

It is more likely to happen if antibiotics aren't taken at the right dose, or for the right length of time.

You should only use antibiotics prescribed to you for a certain condition.Not "leftover" ones, or ones prescribed to someone else. They may not be adequate to kill your infection, and could contribute to bacteria becoming antibiotic-resistant.

And a final way we can fight against antibiotic resistance?Not using them unnecessarily like for the common cold.

This column is part of CBC's Opinion section. For more information about this section, please readour FAQ.

See the original post here:
Sorry, there's no cure for the common cold: Opinion - CBC.ca

Read the Rest...

NanoRobotics Market Overview on Future Threats by 2026 – Crypto News Byte

§ November 25th, 2019 § Filed under Nano Medicine Comments Off on NanoRobotics Market Overview on Future Threats by 2026 – Crypto News Byte

According to Stratistics MRC, the Global Nanorobotics Market is accounted for $4.10 Billion in 2017 and is expected to reach $11.88 Billion by 2026 growing at a CAGR of 12.5% during the forecast period. Growing application of nanotechnology and regenerative medicine, rising acceptance and preferment of entrepreneurship and increasing investments by government and universities are the key factors fuelling the market growth. However, high manufacturing cost may hinder the growth of the market.

Nanorobotics is an evolving technology arena that creates robots or machines which have machinery near to the scale of a nanometre (109 meters). It denotes the nanotechnology engineering regulation of planning, designing, and building nanorobots, primarily from molecular components. Nanorobotics is an attractive new field, especially in medicine, which focus on directed drug delivery using nanoscale molecular machines.

Request For Report sample @: https://www.trendsmarketresearch.com/report/sample/11327

By Type, Nanomanipulator is expected to hold considerable market growth during the forecast period. Nanomanipulator is a specialized nanorobot and microscopic viewing system for working with objects on an extremely small scale. Nanomanipulators are mainly used to influence the atoms and molecules and were among the first nanorobotic systems to be commercially accessible. By geography, Europe dominated the highest market share due to rising aging population and rising governmental healthcare expenditure.

Some of the key players in Nanorobotics include Bruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract and Nanonics Imaging

Types Covered: Nanomanipulator Magnetically Guided Bacteria-Based Bio-Nanorobotics

Applications Covered: Biomedical Nanomedicine Mechanical Other Applications

Request For Discount On This Report at: https://www.trendsmarketresearch.com/report/discount/11327

Regions Covered: North Americao USo Canadao Mexico Europeo Germanyo UKo Italyo Franceo Spaino Rest of Europe Asia Pacifico Japano Chinao Indiao Australiao New Zealando South Koreao Rest of Asia Pacific South Americao Argentinao Brazilo Chileo Rest of South America Middle East & Africao Saudi Arabiao UAEo Qataro South Africao Rest of Middle East & Africa

What our report offers: Market share assessments for the regional and country level segments Market share analysis of the top industry players Strategic recommendations for the new entrants Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) Strategic recommendations in key business segments based on the market estimations Competitive landscaping mapping the key common trends Company profiling with detailed strategies, financials, and recent developments Supply chain trends mapping the latest technological advancements

Free Customization Offerings:All the customers of this report will be entitled to receive one of the following free customization options: Company Profilingo Comprehensive profiling of additional market players (up to 3)o SWOT Analysis of key players (up to 3) Regional Segmentationo Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check) Competitive Benchmarkingo Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Read more:
NanoRobotics Market Overview on Future Threats by 2026 - Crypto News Byte

Read the Rest...

« Older Entries Newer Entries »



Page 9«..891011..2030..»